Literature DB >> 1467532

Trial of recombinant human erythropoietin: three patients with thalassemia intermedia.

N F Olivieri, M H Freedman, S P Perrine, G J Dover, B Sheridan, D L Essentine, R L Nagel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1467532

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.

Authors:  Carla Casu; Mariateresa Pettinato; Alison Liu; Mariam Aghajan; Vania Lo Presti; Maria Rosa Lidonnici; Kevin A Munoz; Emir O'Hara; Violante Olivari; Simona Maria Di Modica; Sheri Booten; Shuling Guo; Garry Neil; Reem Miari; Nir Shapir; Inbal Zafir-Lavie; Hagit Domev; Giuliana Ferrari; Despina Sitara; Antonella Nai; Stefano Rivella
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

2.  Low doses of rHuEPO administered to adult patients with thalassemia intermedia.

Authors:  F Dore; E Gaviano; S Bonfigli; S Pardini; P Pistidda; L Guiso; M Longinotti
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

3.  Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts.

Authors:  N Naffakh; A Henri; J L Villeval; P Rouyer-Fessard; P Moullier; N Blumenfeld; O Danos; W Vainchenker; J M Heard; Y Beuzard
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 4.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

5.  The antioxidant effect of erythropoietin on thalassemic blood cells.

Authors:  Johnny Amer; Mutaz Dana; Eitan Fibach
Journal:  Anemia       Date:  2010-12-21

6.  Involvement of phosphatases in proliferation, maturation, and hemoglobinization of developing erythroid cells.

Authors:  Eitan Fibach
Journal:  J Signal Transduct       Date:  2011-07-14

Review 7.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.